Get started
Author

Surekha Tennakoon

Observed names: G. Surekha Tennakoon, Gayani S Tennakoon, Gayani S. Teenakoon, S. Tennakoon, Surekha Tenakoon, Tenakoon, S, Tenakoon, Surekha, Tennakoon, S, Tennakoon, Surekha
Observed institutions: The Royal Melbourne Hospital, Burnet Institute, The University of Melbourne, Peter MacCallum Cancer Centre, The Alfred Hospital, Victorian Comprehensive Cancer Centre, Peter Doherty Institute, Alfred Health, Monash University
ORCID: 0000-0002-7919-7226
Observed ORCID: 0000-0002-7919-7226
OpenAlex ID: A5029372549
Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging
2013 · Edwin Leeansyah, Paul U. Cameron, et al. · The Journal of Infectious Diseases · 137
Impact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study
2021 · Thomas A Rasmussen, Lakshmi Rajdev, et al. · Clinical Infectious Diseases · 81
Diverse effects of interferon alpha on the establishment and reversal of HIV latency
2020 · Renée M. Van der Sluis, Jennifer M. Zerbato, et al. · PLoS Pathogens · 50
PDF
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
2020 · Eugène D.M.B. Kroon, Jintanat Ananworanich, et al. · Journal of Virus Eradication · 43
The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial
2018 · Thomas A Rasmussen, James H McMahon, et al. · The Lancet HIV · 41
Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection
2020 · Kasha P. Singh, Jennifer M. Zerbato, et al. · PLoS Pathogens · 36
PDF
The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy
2021 · Jillian S.Y. Lau, James H. McMahon, et al. · AIDS · 34
HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF-κB
2016 · Suha Saleh, Hao K. Lu, et al. · Retrovirology · 34
PDF
Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1
2018 · Christina C. Chang, Vivek Naranbhai, et al. · AIDS · 33
PDF
HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy
2022 · Jennifer M. Zerbato, Anchalee Avihingsanon, et al. · EBioMedicine · 30
PDF
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
2023 · Thi H.O. Nguyen, Louise C. Rowntree, et al. · Cell Reports Medicine · 24
Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy
2017 · James H. McMahon, Judy Chang, et al. · AIDS · 19
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19-22 July 2015, Vancouver, Canada
2015 · Pate, KM, Pohlmeyer, C, et al. · Journal of the International AIDS Society · 16
PDF
No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
2014 · Ajantha Solomon, Surekha Tennakoon, et al. · PLoS ONE · 16
PDF
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal
2021 · James H. McMahon, Vanessa A. Evans, et al. · AIDS · 13
Influenza Vaccination Strategies in Patients with Hematologic Cancer
2025 · Victoria G. Hall, Olivia C. Smibert, et al. · New England Journal of Medicine · 11
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy
2017 · Talia M. Mota, Thomas A. Rasmussen, et al. · AIDS · 10
Neurotoxicity with high dose disulfiram and vorinostat used for HIV latency reversal
2022 · Mcmahon, JH, Evans, VA, et al. · UCL Discovery (University College London) · 8
PDF
Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy
2024 · Kasha P. Singh, Anchalee Avihingsanon, et al. · EBioMedicine · 6
PDF
Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy
2023 · Thi H. O. Nguyen, Chhay Lim, et al. · eJHaem · 6
PDF
Costs associated with invasive Scedosporium and Lomentospora prolificans infections: a case-control study
2023 · Chin Fen Neoh, Sharon C A Chen, et al. · Journal of Antimicrobial Chemotherapy · 5
Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
2023 · Victoria G Hall, Thi H O Nguyen, et al. · Open Forum Infectious Diseases · 4
PDF
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
2025 · Michelle K Yong, Karin Thursky, et al. · Clinical Infectious Diseases · 2
PDF
Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T‐cell period: Preservation of vaccine‐associated antibodies between 0 and 6 months
2024 · Gemma K. Reynolds, Emily Klimevski, et al. · British Journal of Haematology · 2
High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post–Autologous Stem Cell Transplant Period
2023 · Victoria G Hall, Natalie R Saunders, et al. · Open Forum Infectious Diseases · 2
PDF
Works count: 48
Citation count: 667
H-index: 14
I10-index: 17
Year
Topic
Type